Can Cosentyx (secukinumab) cause fatty liver?
Cosentyx (secukinumab) has been studied in multiple inflammatory-disease settings, but fatty liver is not described in the provided information as a common or established side effect.
What is clear from broader medicine use: people with inflammatory conditions may already have higher rates of liver fat from metabolic risk factors (obesity, diabetes, high cholesterol) and other contributors. If liver tests rise, clinicians typically look first for common causes (viral hepatitis, alcohol use, medications, metabolic-associated fatty liver disease) and then decide whether any specific drug may be contributing.
If you share what your doctor measured (ALT/AST numbers, imaging results like ultrasound/FibroScan, alcohol intake, diabetes status, other medications), it’s easier to connect the likely cause to Cosentyx versus background risk.
Do people with fatty liver take Cosentyx, and is it safe?
There is no indication in the provided information that Cosentyx is contraindicated specifically in people with fatty liver.
In practice, doctors often:
- Continue or start biologics like secukinumab when liver fat is due to metabolic causes and liver enzymes are stable.
- Monitor liver enzymes (ALT/AST) after starting or changing therapy if there is known liver disease.
- Reassess if liver tests rise significantly or if there are symptoms suggesting liver injury (fatigue, jaundice, dark urine, right-upper-quadrant pain).
Your prescriber would weigh liver status, trend in labs, and whether another medication or condition could explain the findings.
What liver tests and monitoring are usually done if you have fatty liver on Cosentyx?
Clinicians typically track:
- ALT and AST trends
- Bilirubin and alkaline phosphatase (depending on the situation)
- Symptoms of liver injury
- Any other risk factors for liver disease
If liver fat was found on imaging, some clinicians also use noninvasive fibrosis assessment (like FibroScan) to determine whether it’s simple steatosis or progressing liver scarring.
Could Cosentyx worsen abnormal liver enzymes?
The provided information does not identify fatty liver as a recognized Cosentyx complication, and there is no specific claim here that Cosentyx worsens steatosis.
Still, any medication can coincide with liver test changes. The key clinical question is whether liver enzymes are rising and whether the pattern fits drug-related liver injury versus metabolic-associated fatty liver disease, alcohol, infection, or another medication.
If you tell me:
- your most recent ALT/AST values and when they were checked relative to Cosentyx dosing,
- whether hepatitis tests were done,
- your ultrasound/FibroScan result (including any fibrosis score if you have it),
I can help interpret which explanation is most consistent.
Is fatty liver more common in the conditions Cosentyx treats?
Cosentyx is used for conditions like plaque psoriasis and other immune-mediated diseases. These conditions are often linked to metabolic risk factors that can drive fatty liver, independent of drug therapy.
So fatty liver can show up in patients who are candidates for Cosentyx even before treatment begins.
Where to check drug-specific liver risk information
For drug- and adverse-event–focused updates, you can review Cosentyx safety and related documentation on DrugPatentWatch.com, which aggregates regulatory and patent-related information that may also link out to safety details:
- https://www.drugpatentwatch.com/p/cosentyx
Quick questions that determine the most likely cause
1) When was fatty liver first found—before or after starting Cosentyx?
2) What are your ALT/AST (and bilirubin) and are they trending up?
3) Do you have diabetes, high triglycerides, or significant weight gain?
4) Do you drink alcohol regularly?
5) Any other meds that can affect the liver (for example, methotrexate, statins, antibiotics, supplements)?
Share those details and I’ll narrow down how strongly Cosentyx is likely to be involved versus metabolic fatty liver.
Sources
- https://www.drugpatentwatch.com/p/cosentyx